Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
about
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and preventionEMT, CTCs and CSCs in tumor relapse and drug-resistanceEffect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coPredicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data BaseLeveraging the power of pooled data for cancer outcomes researchAssociation between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setA simulation model of colorectal cancer surveillance and recurrence.The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer.Overexpression of POSTN in Tumor Stroma Is a Poor Prognostic Indicator of Colorectal CancerTwo or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and CEffect of M1a and M1b category in metastatic colorectal cancer.Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRICapecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.Surveillance for asymptomatic recurrence in resected stage III colon cancer: does it result in a more favorable outcome?Mining the ACCENT database: a review and updatemiR-21 and miR-145 cooperation in regulation of colon cancer stem cells.Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma.Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival.Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer OutcomeStromal Expression of MicroRNA-21 in Advanced Colorectal Cancer Patients with Distant Metastases.Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapyImpact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence.Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy ConsortiumEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Colorectal cancer surveillance: what's new and what's nextMiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.Epidemiology and biology of physical activity and cancer recurrence.Clinicopathologic parameters associated with postoperative complications and risk factors for tumor recurrence and mortality after tumor resection of patients with colorectal cancer.Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study.High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axisReal-world experience with colorectal cancer chemotherapies: patient web forum analysis.Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs.Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
P2860
Q26742027-763C07E2-1FE2-4970-A047-A4CB97109E42Q28082935-0153BD01-D443-417F-B8DA-F2CDFA5BED12Q30316930-B9F9D54B-1A10-48A4-8E4F-9F6CEF62C13FQ31049742-705CD0D0-EEC9-4B05-92DE-E25833B0DE5BQ31119154-4EDDF7D4-5EC7-4356-9ED9-D35F1131F62FQ33518321-77C66B70-86F4-447F-8477-2BB7EC884B96Q33613715-42439089-D358-474B-99AC-F58075214CE8Q33705036-36FDD452-F0A0-4200-8EDE-1FED32EDE9EDQ33729676-E46EF3A3-B594-4AB8-877B-FE4F63F0ACA5Q33800611-6E2D727A-44C8-47DB-B0FF-BB05E524F6F8Q33829754-ED9623F0-D0A9-4831-8F65-7A21A58DD1ACQ33887066-1282DA17-1FE0-48E7-B9B0-9B92883ECA7DQ34108206-A9283C1A-EFE7-4D1D-A094-92A226F1AF75Q34649050-65F18F8F-C9BF-4B8F-A01C-0046060479DCQ35419441-148CE301-E36B-4876-9C82-33D02321DE75Q35530394-D93889B1-3A60-46AD-8AFC-5DD3C366B692Q35556332-6DBFF6F5-DF05-4B6A-860B-601343A4F9EEQ35926157-6286B54B-6B77-45A9-A819-0B5BE2EAA263Q36159222-F0B9A6FB-F2DF-47F1-AB40-53A5259F7F6AQ36223053-5460C88E-4EF3-49CA-9633-E19FA7F86C8DQ36656187-4C595F34-8D56-4D26-A462-0A93B37E963AQ37133241-A38D921D-071D-4283-B6DA-1BA4DE5FE0B8Q37161846-01F728D2-40DD-4082-9381-30FB7C2B89D9Q37282414-C3B58680-E88C-4824-BDF5-A0C727F6BAABQ37310011-5021F42E-EAB5-47AE-AE83-3FDE6C8B7C0DQ37391705-104245D2-F09D-4E0E-806A-3839370BD1B9Q37408810-240E7364-052C-4310-9611-9325F2AF75A7Q37602712-29E55970-AEF0-441D-92C4-FF879DC5AD7FQ37682257-FD80AFCC-2500-4D8E-9BED-10D9E1833ABEQ38051449-E4378674-5D53-4E45-A1EC-2617B3B8C7D0Q38629758-76588970-E16D-4763-B69D-7F482B7D8F7BQ38670369-B42C6779-8FE4-46B2-8BD3-43072481F8E2Q38677921-E8666C7C-6AC9-4A5E-8574-B28F1E4FD394Q38825662-AE0C3E10-4048-4014-B483-A0CDD3ED1012Q38838849-9D2CA722-5DFF-4DBC-95C6-209F53980C3AQ38864520-D087A8C5-6A21-482A-B4E6-8E02E91A463EQ39305060-96BA30F6-1CA5-40CA-BC4F-AAE5C44E50FCQ39371265-CB86FA71-84F2-42DE-937D-114CED89E0B7Q39601118-1C624197-53EF-4CC4-8CC6-A720A16CB49CQ39834388-8F5A6AB2-67D4-4213-90F0-84B37E352A2D
P2860
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Survival following recurrence ...... ings from the ACCENT data set.
@ast
Survival following recurrence ...... ings from the ACCENT data set.
@en
type
label
Survival following recurrence ...... ings from the ACCENT data set.
@ast
Survival following recurrence ...... ings from the ACCENT data set.
@en
prefLabel
Survival following recurrence ...... ings from the ACCENT data set.
@ast
Survival following recurrence ...... ings from the ACCENT data set.
@en
P2093
P356
P1476
Survival following recurrence ...... dings from the ACCENT data set
@en
P2093
Axel Grothey
Daniel G Haller
Jacqueline K Benedetti
Jean-François Seitz
Megan E Campbell
Michael J O'Connell
Richard M Goldberg
P304
P356
10.1200/JCO.2007.15.8261
P407
P577
2008-05-01T00:00:00Z